{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T16:12:59Z","timestamp":1774714379826,"version":"3.50.1"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T00:00:00Z","timestamp":1631232000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"National Natural Science Foundation of Guangxi Province","award":["2018GXNSFAA281159"],"award-info":[{"award-number":["2018GXNSFAA281159"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Huachansu injection (HCS) is a widely used traditional Chinese medicine for advanced non-small cell lung cancer (NSCLC) to alleviate the adverse drug reactions (ADRs) and enhance the clinical efficacy of chemotherapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Objective:<\/jats:title>\n            <jats:p>To evaluate the efficacy and safety of HCS as an adjunctive treatment to platinum-based chemotherapy (PBC) for advanced NSCLC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>A systematic review and meta-analysis were conducted according to PRISMA guidelines. A total of nine databases were searched to select randomized controlled trials (RCTs) of HCS plus PBC to treat NSCLC from inception to October 10, 2020. RCTs on HCS plus PBC vs PBC alone for advanced NSCLC were included. Dichotomous data were pooled as risk ratio (RR) with 95% confidence intervals. RCTs compared to HCS plus PBC vs PBC alone were included. Primary outcomes were objective response rate (ORR) and disease control rate (DCR), and secondary outcomes were survival rate, quality of life (QOL), and adverse drug reactions (ADRs). GRADE software was used to access the quality of evidence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A total of 32 RCTs, including 2753 patients, were included. Compared to PBC alone, HCS plus PBC improved the ORR, DCR, 1- and 2-year survival rates, and QOL and alleviated neutropenia, thrombocytopenia, nausea, vomiting, anemia, liver injury, renal injury, and alopecia.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Compared to PBC alone, HCS plus PBC improved the clinical efficacy and alleviated the ADRs in advanced NSCLC patients. Considering the limitations of the included RCTs, high-quality trials with longer follow-ups are needed to further confirm the results.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000027161","type":"journal-article","created":{"date-parts":[[2021,9,10]],"date-time":"2021-09-10T13:02:06Z","timestamp":1631278926000},"page":"e27161","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Clinical efficacy and safety of Huachansu injection combination with platinum-based chemotherapy for advanced non-small cell lung cancer"],"prefix":"10.1097","volume":"100","author":[{"given":"Xinmei","family":"Tan","sequence":"first","affiliation":[{"name":"Department of anesthesiology, The People's Hospital of Hechi, Hechi, Guangxi, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xueyan","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, People's Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiaxi","family":"Xi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, People's Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sitong","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, People's Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingyu","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, People's Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, People's Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3901-0727","authenticated-orcid":false,"given":"Yan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, People's Republic of China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,9,10]]},"reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41571-020-00432-6","article-title":"Lung cancer LDCT screening and mortality reduction\u2014evidence, pitfalls and future perspectives","volume":"18","author":"Oudkerk","year":"2021","journal-title":"Nat Rev Clin Oncol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"07","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics, 2020","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J Clin"},{"issue":"(Suppl 2)","key":"R3-20250504","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.21037\/tlcr.2019.08.10","article-title":"Current landscape of palliative radiotherapy for non-small-cell lung cancer","volume":"8","author":"Jumeau","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"245","DOI":"10.21037\/atm.2020.01.118","article-title":"Perioperative chemoimmunotherapy in a patient with stage IIIB non-small cell lung cancer","volume":"8","author":"Liang","year":"2020","journal-title":"Ann Transl Med"},{"issue":"(Suppl 5)","key":"R5-20250504","doi-asserted-by":"crossref","first-page":"v52","DOI":"10.1093\/annonc\/mdj950","article-title":"Chemo-radiotherapy in non-small cell lung cancer: the role of gemcitabine","volume":"17","author":"Trodella","year":"2006","journal-title":"Ann Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.3389\/fonc.2019.01219","article-title":"Stereotactic body radiotherapy for oligometastatic disease in non-small cell lung cancer","volume":"9","author":"Wujanto","year":"2019","journal-title":"Front Oncol"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/S1470-2045(12)70139-0","article-title":"Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: a randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301)","volume":"13","author":"Atagi","year":"2012","journal-title":"Lancet Oncol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/S1470-2045(16)30410-7","article-title":"Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial","volume":"17","author":"Sun","year":"2016","journal-title":"Lancet Oncol"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10147-011-0304-5","article-title":"Tubular nephrotoxicity induced by docetaxel in non-small-cell lung cancer patients","volume":"17","author":"Takimoto","year":"2012","journal-title":"Int J Clin Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1038\/sj.bjc.6602759","article-title":"A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC","volume":"93","author":"Michael","year":"2005","journal-title":"Br J Cancer"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1200\/JCO.2012.44.5064","article-title":"New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer","volume":"31","author":"Salama","year":"2013","journal-title":"J Clin Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"e12734","DOI":"10.1111\/ecc.12734","article-title":"Systemic therapy treatment patterns in patients with advanced non-small cell lung cancer (NSCLC): PIvOTAL study","volume":"26","author":"de Castro","year":"2017","journal-title":"Eur J Cancer Care"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.lungcan.2019.07.010","article-title":"Efficacy and safety of first-line carboplatin-versus cisplatin-based chemotherapy for non-small cell lung cancer: a meta-analysis","volume":"135","author":"Griesinger","year":"2019","journal-title":"Lung Cancer"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/CCO.0000000000000266","article-title":"Novel cytotoxic drugs in advanced nonsmall cell lung cancer","volume":"28","author":"Gridelli","year":"2016","journal-title":"Curr Opin Oncol"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0169-5002(02)00394-X","article-title":"First-line chemotherapy for NSCLC: an overview of relevant trials","volume":"38","author":"Belani","year":"2002","journal-title":"Lung Cancer"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1200\/JCO.2000.18.1.122","article-title":"Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer","volume":"18","author":"Sandler","year":"2000","journal-title":"J Clin Oncol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1200\/JCO.1998.16.7.2459","article-title":"Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: a Southwest Oncology Group study","volume":"16","author":"Wozniak","year":"1998","journal-title":"J Clin Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2005.07.172","article-title":"Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730)","volume":"23","author":"Lilenbaum","year":"2005","journal-title":"J Clin Oncol"},{"key":"R19-20250504","first-page":"4728","article-title":"Meta-analysis of Cinobufacini injection combined with platinum-contained first-line chemotherapy in treatment of non-small cell lung cancer","volume":"44","author":"Xu","year":"2019","journal-title":"China J Chin Mater Med"},{"key":"R20-20250504","first-page":"59","article-title":"Clinical efficacy of cinobufacin capsules combined with chemotherapeutic drugs in the treatment of non-small cell lung cancer: a meta-analysis","volume":"16","author":"Huang","year":"2018","journal-title":"Clin Med J"},{"key":"R21-20250504","first-page":"67","article-title":"Meta-Analysis of cinobufacini injection plus chemotherapy in the treatment of non-small-cell lung cancer","volume":"2","author":"Tu","year":"2012","journal-title":"Antitumor Pharm"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"01","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst Rev"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/1097-0142(19800415)45:8<2220::AID-CNCR2820450835>3.0.CO;2-Q","article-title":"Evaluation of patients with advanced cancer using the Karnofsky performance status","volume":"45","author":"Yates","year":"1980","journal-title":"Cancer"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/1471-2288-9-80","article-title":"Meta-Analyst: software for meta-analysis of binary, continuous and diagnostic data","volume":"9","author":"Wallace","year":"2009","journal-title":"BMC Med Res"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1002\/sim.2380","article-title":"A modified test for small-study effects in meta-analyses of controlled trials with binary endpoints","volume":"25","author":"Harbord","year":"2006","journal-title":"Stat Med"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.0006-341X.2000.00455.x","article-title":"Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis","volume":"56","author":"Duval","year":"2000","journal-title":"Biometrics"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting results of cancer treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1111\/j.1349-7006.2003.tb01394.x","article-title":"Tumor response to chemotherapy: the validity and reproducibility of RECIST guidelines in NSCLC patients","volume":"94","author":"Watanabe","year":"2003","journal-title":"Cancer science"},{"key":"R31-20250504","first-page":"233","article-title":"Clinical efficacy of cinobufacini injection for advanced non-small cell lung cancer","volume":"48","author":"Hao","year":"2016","journal-title":"Inner Mongolia Med J"},{"key":"R32-20250504","first-page":"70","article-title":"Clinical research on non-small cell lung cancer treated by cinobutacini injection plus chemotherapy","volume":"33","author":"Wang","year":"2006","journal-title":"Central Plains Med J"},{"key":"R33-20250504","first-page":"463","article-title":"Clinical study of combined huachansu with chemotherapy on advanced non-small cell lungs cancer","volume":"14","author":"Liu","year":"2007","journal-title":"Chin J Clin Oncol Rehabil"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/jcph.191","article-title":"Prediction of overall survival or progression free survival by disease control rate at week 8 is independent of ethnicity: Western versus Chinese patients with first-line non-small cell lung cancer treated with chemotherapy with or without bevacizumab","volume":"54","author":"Claret","year":"2014","journal-title":"J Clin Pharmacol"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/S0959-8049(97)00325-0","article-title":"Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10\u200ayears experience of the European Lung Cancer Working Party","volume":"33","author":"Paesmans","year":"1997","journal-title":"Eur J Cancer"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/jssc.201200762","article-title":"Qualitative and quantitative analysis of cinobufacini injection using rapid separation liquid chromatography coupled with quadrupole-time-of-flight mass spectrometry and HPLC-photodiode array detection, a feasible strategy for the quality control of Chinese medicine injections","volume":"36","author":"Zhao","year":"2013","journal-title":"J Sep Sci"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1248\/cpb.16.1140","article-title":"Gas liquid chromatography of steroids of Ch\u2019an Su. II. Reinvestigation on the determination of bufadienolides","volume":"16","author":"Sakurai","year":"1968","journal-title":"Chem Pharm Bull"},{"key":"R39-20250504","first-page":"623","article-title":"A new bufadienolide with cytotoxic activity from the Chinese traditional drug Ch\u2019an Su","volume":"12","author":"Xu","year":"2014","journal-title":"Chin J Nat Med"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s12935-019-0806-1","article-title":"New therapeutic aspects of steroidal cardiac glycosides: the anticancer properties of Huachansu and its main active constituent Bufalin","volume":"19","author":"Cheng","year":"2019","journal-title":"Cancer Cell Int"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/02791072.2000.10400456","article-title":"Bufotenine: toward an understanding of possible psychoactive mechanisms","volume":"32","author":"McBride","year":"2000","journal-title":"J Psychoactive Drugs"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/j.intimp.2010.12.007","article-title":"Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor","volume":"11","author":"Qi","year":"2011","journal-title":"Int Immunopharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027161","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:37:21Z","timestamp":1746333441000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000027161"}},"subtitle":["A systematic review and meta-analysis of randomized controlled trials"],"short-title":[],"issued":{"date-parts":[[2021,9,10]]},"references-count":41,"journal-issue":{"issue":"36","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000027161","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,10]]},"assertion":[{"value":"2021-04-28","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-08-17","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}